Related Experiment Video

Updated: Jul 20, 2026

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples
05:17

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Published on: July 28, 2016

Plasma myeloperoxidase levels in patients with chronic heart failure

W H Wilson Tang1, Marie-Luise Brennan, Kiran Philip

  • 1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA. tangw@ccf.org

The American Journal of Cardiology
|September 5, 2006
PubMed

Insights

Plasma myeloperoxidase (MPO) levels are significantly elevated in patients with chronic heart failure (HF). Higher MPO levels correlate with increased HF severity and poorer functional class.

Area of Science:

  • Biochemistry
  • Cardiology
  • Inflammation Research

Background:

  • Chronic heart failure (HF) is associated with oxidative stress and endothelial dysfunction.
  • Myeloperoxidase (MPO) is an inflammatory marker implicated in cardiovascular disease.
  • The relationship between MPO levels and chronic HF severity was previously unreported.

Purpose of the Study:

  • To investigate the association between plasma MPO levels and the severity of chronic systolic heart failure.
  • To examine the correlation of MPO with B-type natriuretic peptide and left ventricular ejection fraction in HF patients.

Main Methods:

  • Plasma MPO levels were measured in 102 patients with chronic systolic HF and 105 healthy controls.
  • MPO levels were analyzed in relation to New York Heart Association (NYHA) functional class.
  • Correlations with plasma B-type natriuretic peptide and left ventricular ejection fraction were assessed.

Main Results:

  • Plasma MPO levels were significantly higher in HF patients compared to controls (1,158 +/- 2,965 vs 204 +/- 139 pM, p <0.0001).
  • MPO levels increased with worsening NYHA class (p <0.0001) and correlated with B-type natriuretic peptide (r = 0.39, p <0.0001).
  • Elevated MPO was strongly associated with HF prevalence, remaining significant after adjustment for covariates (OR 27.7).

Conclusions:

  • Plasma MPO levels are elevated in patients with chronic heart failure.
  • MPO levels are associated with increased HF severity and functional class.
  • MPO may serve as a relevant biomarker in chronic heart failure management.

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...